Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed neurologic impairment and improved renal da...
Enregistré dans:
Auteurs principaux: | Ohanian M, Cable CC, Halka KK |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/65e2b59bd0324ba0b6de9db31e3d079a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
par: Halka K, et autres
Publié: (2011) -
Uncommon presentation of atypical hemolytic uremic syndrome: A Case Report
par: Sandra M Martin, et autres
Publié: (2021) -
Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
par: Hong Si Nga, et autres
Publié: (2021) -
Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort
par: Hong Si Nga, et autres
Publié: (2021) -
SOLUBLE ADHESION MOLECULES IN CHILDREN WITH HEMOLYTIC UREMIC SYNDROME
par: T. E. Pankratenko, et autres
Publié: (2018)